Trial · NCT01798485
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival as of 19 October 2015 | Ganetespib and Docetaxel | 10.9 | 95% Confidence Interval 9.0 to 12.3 | months | |
| Overall Survival as of 19 October 2015 | Docetaxel | 10.5 | 95% Confidence Interval 8.6 to 12.2 | months | |
| Progression-free Survival (PFS) as of 19 October 2015 | Ganetespib and Docetaxel | 4.2 | 95% Confidence Interval 3.8 to 4.4 | months | |
| Progression-free Survival (PFS) as of 19 October 2015 | Docetaxel | 4.3 | 95% Confidence Interval 3.6 to 5.6 | months | |
| Overall Survival (OS) In Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015 | Ganetespib and Docetaxel | 7.1 | 95% Confidence Interval 5.4 to 11.0 | months | |
| Overall Survival (OS) In Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015 | Docetaxel | 9.0 | 95% Confidence Interval 6.2 to 10.3 | months | |
| Objective Response Rate (ORR) as of 19 October 2015 | Ganetespib and Docetaxel | 13.7 | 95% Confidence Interval 10.2 to 17.9 | percentage of participants | |
| Objective Response Rate (ORR) as of 19 October 2015 | Docetaxel | 16.0 | 95% Confidence Interval 12.3 to 20.4 | percentage of participants | |
| Disease Control Rate (DCR) as of 19 October 2015 | Ganetespib and Docetaxel | >=6 weeks | 64.9 | 95% Confidence Interval 59.1 to 69.6 | percentage of participants |
| Disease Control Rate (DCR) as of 19 October 2015 | Docetaxel | >=6 weeks | 60.8 | 95% Confidence Interval 55.4 to 66.1 | percentage of participants |
| Disease Control Rate (DCR) as of 19 October 2015 | Ganetespib and Docetaxel | >=12 weeks | 46.0 | 95% Confidence Interval 40.5 to 51.5 | percentage of participants |
| Disease Control Rate (DCR) as of 19 October 2015 | Docetaxel | >=12 weeks | 46.9 | 95% Confidence Interval 41.5 to 52.4 | percentage of participants |
| Kaplan-Meier Estimate of Duration of Response (DOR) as of 19 October 2015 | Ganetespib and Docetaxel | 5.8 | 95% Confidence Interval 3.0 to 5.9 | months | |
| Kaplan-Meier Estimate of Duration of Response (DOR) as of 19 October 2015 | Docetaxel | 5.8 | 95% Confidence Interval 4.3 to 6.9 | months | |
| Progression Free Survival (PFS) in Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015 | Ganetespib and Docetaxel | 3.0 | 95% Confidence Interval 2.4 to 4.0 | months | |
| Progression Free Survival (PFS) in Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015 | Docetaxel | 2.8 | 95% Confidence Interval 2.2 to 4.1 | months | |
| Kaplan-Meier Estimate for Time to Emergence of New Metastatic Lesion (TNL) as of 19 October 2015 | Ganetespib and Docetaxel | 8.1 | 95% Confidence Interval 6.5 to 9.7 | months | |
| Kaplan-Meier Estimate for Time to Emergence of New Metastatic Lesion (TNL) as of 19 October 2015 | Docetaxel | 8.7 | 95% Confidence Interval 7.2 to 11.6 | months | |
| Percentage of Participants With Progressive Disease Due to Any New Metastatic Lesion as of 19 October 2015 | Ganetespib and Docetaxel | 34.9 | percentage of participants | ||
| Percentage of Participants With Progressive Disease Due to Any New Metastatic Lesion as of 19 October 2015 | Docetaxel | 30.6 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01798485/results